Cogent Biosciences (COGT) Cash from Operations (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Cash from Operations of 86883000.0 for Q1 2026, down 30.63% year-over-year from 125244916.73 in Q1 2025, and down 9.83% quarter-over-quarter from 79105000.0 in Q4 2025.
Cogent Biosciences (COGT) Cash from Operations (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Cash from Operations for 10 consecutive years, with 86883000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 30.63% year-over-year to 86883000.0; the TTM figure through Mar 2026 stood at 284816000.0 (down 28.43% YoY), while the FY2025 annual figure was 264444000.0, down 27.26% from the prior year.
- Cash from Operations fell to 86883000.0 in Q1 2026 per COGT's latest filing, from 79105000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 26456000.0 in Q2 2022 and bottomed at 86883000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 48904705.88 across 5 years, with a median of 44070000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 149.29% — and 2023, when it slipped 10.25%.
- Cogent Biosciences' Cash from Operations stood at 29408000.0 in 2022, then plunged by 49.86% to 44070000.0 in 2023, then tumbled by 37.46% to 60577000.0 in 2024, then slumped by 30.59% to 79105000.0 in 2025, then slipped by 9.83% to 86883000.0 in 2026.
- Business Quant data shows COGT's Cash from Operations at 86883000.0 in Q1 2026, 79105000.0 in Q4 2025, and 64286000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | -77.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.27 Mn |
| Jun 30, 2026 | -77.27 Mn |
| Mar 31, 2026 | -86.88 Mn |
| Mar 31, 2026 | -86.88 Mn |
| Dec 31, 2025 | -79.11 Mn |
| Dec 31, 2025 | -79.11 Mn |
| Sep 30, 2025 | -64.29 Mn |
| Sep 30, 2025 | -64.29 Mn |
| Jun 30, 2025 | -54.54 Mn |
| Jun 30, 2025 | -54.54 Mn |
| Mar 31, 2025 | -66.51 Mn |
| Mar 31, 2025 | -66.51 Mn |
| Dec 31, 2024 | -60.58 Mn |
| Dec 31, 2024 | -60.58 Mn |
| Sep 30, 2024 | -51.98 Mn |
| Sep 30, 2024 | -51.98 Mn |
| Jun 30, 2024 | -42.70 Mn |
| Jun 30, 2024 | -42.70 Mn |
| Mar 31, 2024 | -52.53 Mn |
| Mar 31, 2024 | -52.53 Mn |